Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

Fosbretabulin disodium

HY-17449

(Fosbretabulin disodium salt; CA 4DP; CA 4P; Combretastatin A4 disodium phosphate)

Fosbretabulin disodium

Fosbretabulin disodium Chemical Structure

Fosbretabulin disodium(CA 4DP; CA 4P) is a microtubule destabilizing drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.

Size Price Stock Quantity
10 mM * 1 mL in DMSO $106 In-stock
5 mg $96 In-stock
10 mg $120 In-stock
50 mg $350 In-stock
100 mg Get quote
200 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €104 In-stock
5 mg €94 In-stock
10 mg €118 In-stock
50 mg €343 In-stock
100 mg Get quote
200 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: Fosbretabulin disodium
Cat. No.: HY-17449

Fosbretabulin disodium Data Sheet

  • View current batch:

    Purity: 99.39%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

Related Compound Libraries

Biological Activity of Fosbretabulin disodium

Fosbretabulin disodium(CA 4DP; CA 4P) is a microtubule destabilizing drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.
IC50 Value: 4 nM [1]
Target: microtubule
in vitro: Cytotoxic IC(50) values of CA-4 in human bladder cancer cells were below 4 nM. Analyses of cell-cycle distribution showed CA-4 obviously induced G(2)-M phase arrest with sub-G(1) formation. The analyses of apoptosis showed that CA-4 induced caspase-3 activation and decreased BubR1 and Bub3 in cancer cells [1]. The enhanced apoptosis induced by dasatinib plus CA-4 was accompanied by a greater extent of mitochondrial depolarization, caspase-3 activation and PARP cleavage in HO-8910 cells. Furthermore, elevated expression of Mcl-1 led to a reduced apoptosis induced by dasatinib plus CA-4, highlighting that downregulated Mcl-1 was necessary for the potentiating effect of dasatinib to CA-4-triggered apoptosis [2].
in vivo: The increased anticancer efficacy of dasatinib combined with CA-4 was further validated in a human HO-8910 ovarian cancer xenograft model in nude mice [2]. There was a significant, concentration dependent increase in mean arterial blood pressure with a maximum increase of about 60% of the baseline MAP at 30 mg/kg of CA4P compared to the saline control. However, there was no significant increase in the cardiac troponin I level after CA4P injection [3].
Clinical trial: A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome [4].
 

Chemical Information

M.Wt 440.29 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C₁₈H₁₉Na₂O₈P
CAS No 168555-66-6
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.2712 mL 11.3562 mL 22.7123 mL
5 mM 0.4542 mL 2.2712 mL 4.5425 mL
10 mM 0.2271 mL 1.1356 mL 2.2712 mL

Clinical Information of Fosbretabulin disodium

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
Fosbretabulin disodium OXiGENE Inc Ocular disease 31-JUL-09 31-AUG-10 Phase 2 02-NOV-11
OXiGENE Inc Anaplastic thyroid cancer 30-JUN-13 31-DEC-16 Phase 3 12-SEP-13
National Cancer Institute Fallopian tube cancer 31-MAR-11 Phase 2 05-AUG-13
OXiGENE Inc Anaplastic thyroid cancer 31-JUL-07 31-OCT-11 Phase 3 12-JUN-13
OXiGENE Inc Anaplastic thyroid cancer 31-JUL-07 31-OCT-11 Phase 3 12-JUN-13
OXiGENE Inc Anaplastic thyroid cancer 30-JUN-13 31-DEC-16 Phase 3 12-SEP-13
OXiGENE Inc Choroidal neovascularization 31-MAR-05 31-JAN-07 Phase 2 28-OCT-13

References on Fosbretabulin disodium

Inhibitor Kit

Related Microtubule/Tubulin Products

  • 10-Deacetyl-7-xylosyl paclitaxel

    10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility.

  • 10-Oxo Docetaxel

    10-Oxo Docetaxel(Docetaxel Impurity) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.

  • 2-Methoxyestradiol

    2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 (plusmn) 0.11 (mu)M for the inhibition of BPAEC migration.

  • 4'-Demethylepipodophyllotoxin

    4(acute)-Demethylepipodophyllotoxin(4(acute)-DMEP) is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs; a potent inhibitor of microtubule assembly.

  • 7-Epi-10-oxo-docetaxel

    7-Epi-10-oxo-docetaxel (Docetaxel Impurity D) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).

  • 7-Epi-docetaxel

    7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.

  • 7-xylosyltaxol

    7-xylosyltaxol(Taxol-7-xyloside) is a taxol (Paclitaxel) derivative; Paclitaxel binds to tubulin and inhibits the disassembly of microtubules.

  • ABT-751

    ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 (mu)M in neuroblastoma and non-neuroblastoma cell lines, respectively.

  • Auristatin E

    Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates.

  • Auristatin F

    Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates.

MORE